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Sllmmary 
Immunization protocols that induce high levels of delay~-type hypersensitivity are often associated 
with low levels of antibody production, whereas alternative immunization strategies can produce 
the opposite effect. This reciprocal relationship appears to depend, at least in part, on the fact 
that T ceU-derived lymphokines that are predominantly involved in one type of response inhibit 
the development of those T cells that promote the alternative one. Such a regulatory mechanism 
is likely to be bistable in that whenever one form of response is established, spontaneous development 
of the alternative one will be inhibited. We have applied this concept to the control of a cell- 
mediated autoimmune disease in rats. By covalently linking the autoantigen to anti-IgD antibody, 
we have targeted it to B cells for presentation to antigen-specific T cells. This form of presentation 
favors antibody production and may be expected to antagonize the ceU-mediated disease-inducing 
response to the same antigen. To test this hypothesis, use was made of the fact that experimental 
allergic encephalomyelitis (EAE),  when induced with the encephalitogenic peptide of guinea 
pig myelin basic protein, is purely a cell-mediated disease. The experiments show that Lewis 
rats, immunized with the peptide in its encephalitogenic form, were protected from disease when 
simultaneously injected with the peptide coupled to anti-IgD monoclonal antibodies.  Control 
experiments showed that neither peptide nor anti-IgD alone were protective, and the peptide 
covalently coupled to irrelevant antibodies also failed to protect. Spleen cells from animals protected 
from disease by the anti-IgD-peptide conjugate, when activated in vitro with the encephalitogen, 
were able to transfer EAE to naive recipients. The results demonstrate that a cell-mediated immune 
response can be controlled by appropriate targeting of the specific antigen without inducing 
T cell anergy and suggest a potential strategy for preventing autoimmune  diseases that are essentially 
cell-mediated in type. 
E 
xperimental allergic encephalomyelitis (EAE) is an inflam- 
matory disease of the central nervous system  (CNS) 1 
that can be induced in a number of species of experimental 
animals by the injection of antigenic material obtained from 
brain or spinal cord (1-3).  In Lewis strain rats immunized 
with guinea pig myelin basic protein (MBP), or with a pep- 
tide consisting of amino acid residues 70-86 (4) of the ma- 
ture protein sequence, a focal mononudear cell infiltration 
develops in the CNS white matter 10-11 d after immuniza- 
tion. This reaction is associated with an ascending paralysis 
that first affects the tail and then the hind limbs. Inconti- 
nence develops in ~50%  of the animals.  Remarkably, the 
disease remits spontaneously so that within 5-6 d of the first 
1  Abbreviations  used in thispaper:  CNS, central nervous system; MBP, myelin 
basic protein. 
sign of paralysis, the animals recover completely (5). A single 
episode of relapse is observed in a few percent of animals, 
but in all cases convalescent rats become completely refrac- 
tory to further attempts to reinduce the disease. 
Studies on the effect of adrenalectomy at different stages 
of the disease suggest that, while the spontaneous recovery 
of rats from EAE is a consequence of the immediate im- 
munosuppressive effects of corticosterone released from the 
adrenal glands in response to the stress of the disease (5, 6), 
the refractory phase may represent a stable corticosterone- 
induced change in the balance of lymphokine production to- 
wards those that inhibit cell-mediated immunity and favor 
antibody  synthesis  (7-9).  This  interpretation  of the  ex- 
perimental results rests on the finding that the lymphokines 
involved in cell-mediated immunity and humoral immunity 
are agonists for the response with which they are associated, 
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antagonism provides an explanation for the observation that 
there appears to be a reciprocal relationship between the two 
types of immune reaction  (12).  From these considerations 
it might be anticipated that immunization protocols that in- 
duce those lymphokines involved in humoral immunity would 
antagonize the development of EAE. There is evidence that 
antigen presentation by B cells has such an inductive effect 
(13,  14). 
To promote the presentation to T cells of the encephatito- 
genic peptide of MBP by B cells in the experiments  to be 
described, it was covalently coupled to mAbs that recognize 
rat  IgD.  Anti-IgD  targeting  antibodies were chosen since 
serum levels of IgD are negligible while a high proportion 
of rat B cells express surface IgD (S. V. Hunt, personal com- 
munication;  and D.  W.  Mason,  unpublished  results). 
Materials and Methods 
Animals and the Induction of EAE.  Lewis  strain rats, from our 
own specific pathogen-free facility, were used throughout. To in- 
duce EAE, adult animals of either sex were injected in the hind 
footpads with 50 #g MBP emulsified in CFA (5). In individual 
experiments  all animals were of the same sex. 
Monoclonal Antibodies and the Preparation  of  Antibody-Peptide Con- 
jugates,  mAb MARD-3 against rat IgD was purchased from the 
Experimental Immunology Unit, University of Louvain, Belgium. 
The mAb MKC OX-60, which was derived from a BALB/c mouse 
immunized  with rat thoracic duct lymphocytes, has been shown 
to react with IgD on "~50% of rat IgD + B calls. The reason it 
does not react with all IgD § B cells is not known at present. Im- 
munoprecipitation  studies using MKC OX-60 and MARD-3, and 
inhibition  of binding  of MRC OX-60 mAb with IgD myeloma 
protein, show that this mAb reacts with rat IgD with high affinity 
but with no other rat Ig isotype (15). MKC OX-21 reacts with 
a component  of human complement but not rat tissues (16). All 
three mAbs are mouse IgG1 Igs and were prepared from ascitic 
fluid by sodium sulphate precipitation and ion exchange chroma- 
tography. The F(ab')2 fragment of OX-60 was prepared by pepsin 
digestion,  for 14 h at 37~  of purified OX-60 IgG at pH 4.0, 
using 0.2 nag of enzyme per 1 mg Ig and at a protein concentra- 
tion of 5 mg/ml. 
The mAbs MARD-3, OX-60, OX-60 F(ab')2, and BSA (Sigma 
Chemical Co., Poole, UK) were individually covalently linked to 
the encephalitogenic peptide of MBP by the sulpho-SMCC reagent 
(Pierce Chemical Co., Rockford,  IL). The encephalitogenic Pep- 
tide (4) was synthesized by the Fmoc HOBt/NMP method (17) 
but with a Cys residue added to its NH2 terminus  to facilitate 
coupling by the sulpho-SMCC reagent (full sequence: CGSLPQ- 
KSQRSQDENPVV). 
Transfer of EAE by In Vitro T Cell Activation.  EAE was trans- 
ferred from immunized donors to naive recipients as described (18). 
Briefly, splenocytes from rats immunized  with MBP in CFA, or 
with CFA alone, were stimulated in vitro for 3 d with MBP or 
with the encephalitogenic peptide thereof, and then injected intra- 
venously into syngeneic recipients, The cell doses used for transfer 
are given in Results. 
Immunochemistry.  Portions of the thoracic and lumbar  spinal 
cord were removed from rats in experimental and control groups 
on day 27 after immunization.  5-#m cryostat sections were fixed 
in ethanol at 4~  and stained with mAbs to detect infiltrating hu- 
kocytes using OX-1 and OX-30 mAbs that recognize all isoforms 
of the leukocyte-common antigen  (rat CD45) (19). Bound anti- 
body was detected by an immunoperoxidase technique as described 
(20). Specificity of staining was established by using OX-21 mAb 
in place of the anti-CD45  mAbs. 
Results and Discussion 
Rats were immunized subcutaneously with MBP in CFA 
and injected intravenously on the day of immunization  and 
again 7 d later, with either a control preparation or the en- 
cephalitogenic peptide of MBP conjugated to mouse anti-rat 
IgD mAb.  As Table 1 shows,  the control injections (Exp. 
1, rows 4 and 5: Exp. 3, rows 2 and 3; Exp. 4, Row 2) had 
little effect on the severity of disease,  although the onset of 
disease was a little delayed in some cases. On the other hand, 
intravenous injection of the anti-IgD-peptide conjugates pro- 
duced a dose-dependent suppression of EAE such that most 
animals given two 100-/~g doses developed no detectable signs 
of disease (Exp. 2, row 3; Exp. 5, rows 2, 3, and 4). Animals 
were also protected if a single  100-#g dose was given 7 d 
before immunization with MBP in adjuvant (data not shown), 
but more detailed injection protocols, such as more frequent 
lower doses, have not been examined. Conjugates of the pep- 
tide with anti-IgD F(ab')2 were also protective (Exp.  1, rows 
2 and 3). 
Contrary to expectation,  antipeptide antibody levels, as- 
sayed by solid phase RIA (8), were not elevated in anti-IgD- 
peptide conjugate-protected rats compared with those in the 
control animals  (data not shown).  Sera were assayed from 
bleeds made on days 7,  10,  14, 21, and 25 after immuniza- 
tion, that is, throughout the period of disease development 
in the controls. In principle, any IgD-positive B cell has the 
potential to act as an APC for T cell activation in this system 
(21), whereas only peptide-specific B cells are capable of giving 
rise to antipeptide  antibody-secreting plasma cells.  Conse- 
quently, it is possible that the induction of T cells with the 
ability  to  antagonize  cell-mediated  immunity  can  occur 
without the concomitant production of high levels of specific 
antibody. In systems where B cell-targeted antigen has been 
used to evoke high levels of antibody synthesis, much higher 
doses of antigen  were used (13,  14). 
Immunohistochemical staining of cryostat sections of spinal 
cords from rats in Exp. 5 of Table 1 showed, in the controls, 
heavy focal infiltrates of mononuclear cells that persisted into 
the recovery phase of the disease (day 27) but in  the rats 
receiving anti-IgD-peptide conjugates, results were more vari- 
able. Some animals that showed no clinical  signs of paralysis 
had few if any focal infiltrates in the spinal cord whereas others 
that remained free from disease and those that developed min- 
imal signs had focal infiltrates not strikingly less marked than 
control rats with severe paralysis  (data not shown). This re- 
sult resembles that seen in rats protected from EAE by anti- 
CD4 mAb treatment (18). In these experiments also, marked 
leukocyte infiltration of the CNS was not incompatible with 
near normal neurological function. It is not known in what 
qualitative way disease-inducing infiltrates differ from those 
that  are apparently innocuous. 
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Peak disease score  Statistics 
Exp.  Treatment  (mean score)  vs. controls 
Nil  4,  4,  4,  5,  5  (4.4)  - 
1  50/~g F(ab')20X-60-peptide  0.5,  1,  2  (1.2)  <0.02 
100/~g F(ab')20X-60-peptide  0,  0.5,  1,  1,  2  (0.9)  <0.004 
100/~g BSA-peptide  2, 4,  5,  5, 5  (4.2)  NS 
20/~g peptide  5,  5,  5,  5,  5  (5.0)  NS 
Nil  5,  5,  5,  5,  5  (5.0)  - 
2  50/~g OX-60-peptide  0, 0.5,  1,  1,  1  (0.7)  <0.004 
100 #g OX-60-peptide  0, 0,  0,  0,  1  (0.2)  <0.004 
Nil  2,  2,  5,  5,  5  (3.8)  - 
3  50/~g OX-60 mAb  2,  4,  5,  5,  5  (4.2)  NS 
100/~g  OX-60 mAb  4,  4,  4,  5,  5  (4.4)  NS 
Nil  5,  5,  5  (5.0)  - 
4  100/~g OX-21-peptide  4,  4,  4,  4,  4  (4.0)  <0.02* 
Nil  4,  4,  5,  5,  5  (4.6)  - 
5  100/~g OX-60-peptide  0,  0,  0,  0,  1  (0.2)  <0.004 
100/xg MARD-3-peptide  0, 0, 0, 0,  1  (0.2)  <0.004 
50/~g OX-60-peptide  + 
50 #g MARD-3-peptide  0, 0,  0,  0, 0  (0.0)  <0.004 
All rats were immunized in the hind footpads with 50/~g guinea pig MBP in CFA on day 0 of the experiments. In some cases, control rats received 
injections of PBS intravenously on the day of immunization and again 7 d later, while others received no PBS injections. Injection of PBS had no 
effect and the results of controls given, or not given, PBS have been pooled. All other groups received the stated doses of peptide conjugates in- 
travenously on days 0 and 7. Paralysis was scored on a scale of 1-5 as follows. 1, limp tail; 2, hindlimb weakness; 3, unilateral hindlimb paralysis; 
4, bilateral hindlimb paralysis; 5, bilateral hindlimb paralysis plus urinary incontinence (female) or urinary retention (male). The severity of paralysis 
was assessed daily. Disease reached maximum severity between days 12 and 14 after immunization in all control groups. In those rats treated with 
OX60 peptide that developed low levels of paralysis, this reached its peak on days 15-16. In the table, the peak disease score is recorded for each 
rat within an experimental group and the mean score for the group as a whole is given in parentheses. As indicated, there were five rats in each 
group except in two instances. Statistical significance was evaluated by the Wilcoxon rank-sum test. 
* Note that although there is a statistically signficant difference in the severity of disease between rats injected with OX-21-peptide and controls 
(Exp. 4), the effect is very weak and does not reach significance when compared with, for example, the controls in Exps. 1 and 5. 
In principle, it was possible that presenting the encephalito- 
genic peptide  to CD4 +  T  cells by targeting  it  to B  cells 
resulted in the induction of anergy in the peptide-specific T 
cells (22,  23). Such an effect was not seen in mice injected 
with a polyclonal anti-IgD antibody; instead, this treatment 
induced the synthesis of IL-4 (13), which,  as mentioned in 
the introduction, would be expected to antagonize any cell- 
mediated response to the immunogen.  However, the possi- 
bility that an anti-IgD mAb might induce T  cell anergy has 
not been studied.  To examine the question of anergy in the 
present experiments, a test was made of the ability of spleno- 
cytes from anti-IgD-peptide-treated rats to passively transfer 
EAE. Two groups of eight rats were immunized with MBP 
in CFA but one of these two groups was also injected with 
100/~g OX60-peptide conjugate on days 0 and 7. A control 
group of four rats was  injected with  adjuvant  alone.  Four 
rats in each of the first two groups were observed throughout 
the experiment for signs of EAE and the remaining two sets 
of four were used,  on day 13 after immunization,  as spleen 
cell donors for the passive transfer of EAE. 
As Table 2 shows, most of the rats immunized with MBP 
in CFA developed severe EAE and spleen cells from them, 
when activated in vitro with either MBP or the encephalito- 
genic peptide-induced EAE in recipient animals. Significantly, 
the group of rats protected from EAE by the injection of 
anti-IgD peptide conjugate, while developing little or no dis- 
ease themselves,  also served as donors of transferred EAE. 
As the data show,  the incidence and severity of the disease 
in the recipients was no less than that observed when spleno- 
cytes from nonprotected donors were used to transfer EAE, 
and this was equally true when either whole MBP or the 
encephalitogenic peptide was used in the in vitro activation 
step of the transfer. The third group of rats, immunized with 
adjuvant alone, did not develop EAE, and their splenocytes 
failed to transfer disease after in vitro stimulation with MBP 
or peptide. Evidently the in vivo priming of donors was an 
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Treatment  Peak disease score  Antigen used  Peak disease score in 
of donors  in donors (mean score)  in vitro*  recipients (mean score)  Statistics  vs. controls 
MBP/CFA  0', 4~, 4*, 4*, 0,  4,  4, 4  MBP  1,  1,  1 (1)  - 
(3)  Peptide  1,  1,  1 (1)  - 
MBP/CFA 
+  0', 0', 0', 0', 0, 0,  1,  1  MBP  1,  1,  2 (1.3)  NS 
OX-60-peptide  (0)  Peptide  1,  1, 4  (2)  NS 
CFA  0', 0', 0', 0*  MBP  0,  0, 0  (0)  0.05 
alone  (0)  Peptide  0,  0, 0 (0)  0.05 
Spleen cells from rats protected  from EAE by the injection  of anti-lgD-peptide  conjugate  were assayed  for their ability  to transfer  EAE after  in vitro 
activation with either MBP or the encepthalitogenic  peptide. There were three rats in each recipient group. Splenocytes  from unprotected animals 
or from rats injected with CFA alone served as positive and negative  controls, respectively.  The statistical  data were calculated with respect to the 
positive controls. The majority  of recipients that developed signs of paralysis did so 5 d after cell transfer and had recovered by day 9. The two 
exceptions occurred in the group of three rats that had received cells that had been obtained from unprotected MBP/CFA-immunized  donors and 
that had been stimulated  in vitro with the encephalitogenic  peptide. These rats developed  disease  on days  6 and 7, respectively,  and had both recovered 
by day 9. 
* Spleen cells from donor rats were stimulated in vitro, at 106 cells/ml, with either 2/~g/ml MBP or 2 ~g/ml of the encephalitogenic  peptide. 
After 3 d in culture, 5  x  107 cells were injected into each naive recipient. 
* Animals used as donors of spleen cells for adoptive transfer of EAE. 
essential  step in the adoptive transfer.  These results,  there- 
fore give no indication that the anti-IgD-peptide conjugate 
mediated its protective effect by the induction ofT cell anergy 
but, instead, allowed the in vivo priming of the donor spleno- 
cytes to proceed normally. As with the histological finding 
reported in the previous section, these results are also similar 
to those obtained in rats in which EAE was prevented by 
anti-CD4 mAb treatment in that splenocytes  from animals 
so treated were also found to be fully competent to transfer 
disease after in vitro activation (18). 
EAE can be inhibited in a number of ways, including the 
use of mAbs to CD4 and class. II MHC antigens (24,  25). 
These protocols require the use of relatively large amounts 
of antibody and lack antigen specifidty. Preimmunization with 
liposomes containing MBP (26),  or with large amounts of 
encephalitogen in IFA (27,  28),  also induces refractoriness 
to EAE, possibly by essentially the same mechanism as that 
described herein involving protection by the B cell-targeted 
peptide.  Treatment of rats with mAb to the V~ determinant 
of the TCR or immunizing them with synthetic peptides 
whose amino acid sequences are found in the appropriate VB 
chain have also been reported to prevent EAE (29-31),  but 
it is uncertain how general such approaches might be in other 
autoimmune diseases where more than one Va family may 
be involved. The method of disease control reported here does 
not require the use of adjuvant, is antigen specific, and is 
apparently without side effects. It remains to be established 
whether it has broader applications. 
The data also raise certain possibilities.  In at least  some 
instances,  are suppressor  T  cells simply those that promote 
the reciprocal type of immune response to that which is being 
assayed by the experimenter, and can rheumatoid factor B 
cells, by taking up and processing immune complexes (32), 
influence the lymphokine repertoire of T  cells responding 
to the antigenic component of these complexes? 
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